Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1981 1
2004 1
2005 1
2007 6
2008 2
2009 5
2010 3
2011 3
2012 3
2013 4
2014 3
2015 3
2016 6
2017 2
2018 2
2019 6
2020 8
2021 6
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Pei S, et al. Among authors: gutman ja. Cancer Discov. 2020 Apr;10(4):536-551. doi: 10.1158/2159-8290.CD-19-0710. Epub 2020 Jan 23. Cancer Discov. 2020. PMID: 31974170 Free PMC article.
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Cherry EM, et al. Among authors: gutman ja. Blood Adv. 2021 Dec 28;5(24):5565-5573. doi: 10.1182/bloodadvances.2021005538. Blood Adv. 2021. PMID: 34610123 Free PMC article.
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Pollyea DA, et al. Among authors: gutman ja. Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12. Nat Med. 2018. PMID: 30420752 Free PMC article.
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Winters AC, et al. Among authors: gutman ja. Transplant Cell Ther. 2022 Oct;28(10):694.e1-694.e9. doi: 10.1016/j.jtct.2022.07.022. Epub 2022 Jul 25. Transplant Cell Ther. 2022. PMID: 35902048 Free article.
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Pollyea DA, et al. Among authors: gutman ja. Bone Marrow Transplant. 2022 Feb;57(2):160-166. doi: 10.1038/s41409-021-01476-7. Epub 2021 Oct 13. Bone Marrow Transplant. 2022. PMID: 34645926
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Gutman JA, et al. Haematologica. 2023 Oct 1;108(10):2616-2625. doi: 10.3324/haematol.2023.282681. Haematologica. 2023. PMID: 37051756 Free PMC article. Clinical Trial.
A Case of Fetal-Induced Graft-versus-Host Disease.
Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimarães-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, Aisner DL, Gutman JA. Schreiber AR, et al. Among authors: gutman ja. N Engl J Med. 2023 Aug 17;389(7):668-670. doi: 10.1056/NEJMc2307669. N Engl J Med. 2023. PMID: 37585636 No abstract available.
68 results